Share This Page
Bulk Pharmaceutical API Sources for ONIVYDE
✉ Email this page to a colleague
Bulk Pharmaceutical API Sources for ONIVYDE
| Vendor | Vendor Homepage | Vendor Sku | API Url |
|---|---|---|---|
| TCI (Tokyo Chemical Industry) | ⤷ Get Started Free | I0714 | ⤷ Get Started Free |
| Molport | ⤷ Get Started Free | MolPort-003-666-755 | ⤷ Get Started Free |
| AKos Consulting & Solutions | ⤷ Get Started Free | AKOS015901921 | ⤷ Get Started Free |
| >Vendor | >Vendor Homepage | >Vendor Sku | >API Url |
Bulk Active Pharmaceutical Ingredient (API) Sources for ONIVYDE
Introduction
Onivyde (irinotecan liposomal injection) is an essential chemotherapeutic agent indicated for metastatic pancreatic adenocarcinoma following prior treatment with gemcitabine-based therapy. As a liposomal formulation of irinotecan, ONIVYDE’s efficacy hinges on its proprietary manufacturing process which utilizes active pharmaceutical ingredients (APIs) of high purity. The sourcing of bulk APIs for ONIVYDE—namely irinotecan—is critical to ensuring consistency, efficacy, and regulatory compliance in its production. This article provides a comprehensive overview of the key API sources for ONIVYDE, emphasizing the sourcing landscape, quality considerations, and strategic implications for pharmaceutical manufacturers and stakeholders.
Overview of API in Oncology Pharmaceuticals
Active Pharmaceutical Ingredient (API) defines the pharmacologically active component in a drug product. In oncology applications such as ONIVYDE, APIs like irinotecan underpin the treatment’s therapeutic profile. The integrity, purity, and supply chain security of APIs are vital for manufacturing efficacy and patient safety.
Irinotecan, a semisynthetic derivative of camptothecin, inhibits topoisomerase I, disrupting DNA replication in cancer cells. Its complex synthesis involves multiple steps, including extraction from natural sources or chemical synthesis, and subsequent purification to pharmaceutical standards.
Sources of API for ONIVYDE
1. Proprietary and Commercial API Suppliers
Major pharmaceutical manufacturers and specialized API producers supply irinotecan to the market, often under stringent regulatory oversight, ISO standards, and cGMP compliance. The key suppliers for ONIVYDE's API include:
a. Baxter International (now part of Sandoz/Novartis)
Historically, Baxter International developed and commercialized the liposomal formulation of irinotecan—ONIVYDE—using its proprietary API sourced from multiple manufacturers. Baxter maintained strict qualification and validation of API suppliers, establishing a tiered supply chain to prevent disruptions.
b. Teva Pharmaceutical Industries
Teva actively manufactures generic APIs of irinotecan conforming to regulatory cGMP standards. Their capacity to supply high-quality irinotecan has positioned them as a potential API source for generic liposomal formulations or biosimilars.
c. Sinopharm Corporate
As a leading Chinese pharmaceutical group, Sinopharm produces bulk APIs, including irinotecan, with increasing global regulatory acceptance. Their manufacturing facilities are certified by Chinese NMPA and other international authorities.
d. Jiangsu Hengrui Medicine Co., Ltd.
This Chinese biopharmaceutical company has developed and commercialized irinotecan, exporting it globally. Their APIs are produced under strict quality controls, aligning with international standards to serve as potential sources.
e. Patheon (Part of Thermo Fisher Scientific)
As a contract manufacturing organization (CMO), Patheon offers custom API development and bulk API manufacturing, including irinotecan, adhering to quality specifications required for oncological drugs.
2. Contract Manufacturing and API Synthesis
Many pharmaceutical firms utilize contract manufacturing organizations for API synthesis, enhancing supply chain flexibility and cost efficiency.
-
Synthesis Pathway: Irinotecan’s synthesis usually involves multiple chemical steps starting from naturally derived camptothecin or related derivatives, involving oxidation, esterification, and purification phases.
-
Quality Control: Regulatory bodies such as the FDA, EMA, and NMPA require rigorous batch testing for identity, purity (>99%), residual solvents, and biological activity. Suppliers must demonstrate compliance with ICH Q7 guidelines.
3. API Quality Standards and Regulatory Considerations
To be suitable for use in ONIVYDE, APIs must meet specifications set by the FDA and EMA, including:
- Identity and purity (>99%)
- Absence of residual solvents and impurities
- Consistent batch-to-batch quality
- Proven stability profiles
Regulatory approval depends on comprehensive dossiers, including Batch Records, stability data, and physicochemical characterization.
Supply Chain and Strategic Implications
The sourcing of irinotecan API involves navigating complex global supply chains, balancing cost, quality, and regulatory compliance. Leading suppliers often invest in advanced purification techniques—such as chromatography and crystallization—to meet stringent specifications.
Risks include:
- Geopolitical disruptions affecting Chinese API exports
- Regulatory changes that shift approval status or quality requirements
- Supply shortages due to manufacturing issues or raw material scarcity
Companies adopting dual sourcing strategies, establishing long-term supplier relationships, and investing in quality oversight mitigate these risks.
Market Trends and Future Outlook
The oncology API landscape for drugs like ONIVYDE is evolving with increased pressure for supply resilience and quality. The rise of biosimilars and generics has driven global API production facilities to scale up capacity, often in Asia. Simultaneously, regulatory harmonization efforts aim to streamline approval processes for APIs sourced from approved international manufacturers.
Emerging synthesis methods focus on greener, more efficient production, reducing costs and improving supply security. Governments and industry alliances emphasize transparent, compliant supply chains, particularly critical for oncological APIs with narrow therapeutic windows.
Conclusion
The API sourcing landscape for ONIVYDE is characterized by a convergence of established pharmaceutical manufacturers, specialized API producers, and contract manufacturing organizations. Ensuring high-quality, regulatory-compliant irinotecan sources is vital for maintaining the drug’s efficacy, safety, and availability in the global market. As supply chain complexities increase, downstream manufacturers must prioritize supplier qualification, robust quality assurance, and diversified sourcing to mitigate risks and sustain steady production of this critical oncological agent.
Key Takeaways
- Leading API suppliers for ONIVYDE include established international firms such as Baxter, Teva, Sinopharm, and Jiangsu Hengrui.
- Quality standards for irinotecan API demand >99% purity, rigorous impurity profiling, and compliance with ICH guidelines.
- Supply chain diversification and strategic contracting are essential to ensure consistent API availability amid geopolitical and regulatory risks.
- Advances in synthesis and purification technologies are improving API quality and reducing costs.
- Regulatory diligence and thorough supplier qualification underpin the reliable supply of APIs required for thermally sensitive formulations like ONIVYDE.
FAQs
Q1: What distinguishes the API used in ONIVYDE from standard irinotecan formulations?
A: The API itself is chemically identical; however, ONIVYDE employs a liposomal encapsulation of irinotecan, which enhances its pharmacokinetics and reduces systemic toxicity. The API sourced for ONIVYDE must meet additional quality specifications aligned with its specialized formulation process.
Q2: Are there alternative sources of irinotecan APIs besides Chinese and Western manufacturers?
A: While Chinese and Western firms dominate global API production, emerging producers in India and other Asian countries are expanding capacity. Regulatory acceptance depends on quality certification, process validation, and compliance with international standards.
Q3: How does API sourcing impact regulatory approval for ONIVYDE?
A: Regulatory agencies require detailed documentation on API quality, manufacturing processes, and batch consistency. Variations in API source can influence approval timelines and post-approval compliance, making supplier qualification critical.
Q4: What are the supply chain risks associated with sourcing API for ONIVYDE?
A: Risks include geopolitical tensions, disruptions in raw material supply, regulatory hurdles, and quality inconsistencies. Strategic diversification and proactive supplier qualification mitigate these risks.
Q5: Will new manufacturing technologies influence future API sourcing for oncology drugs like ONIVYDE?
A: Yes, innovations such as greener synthesis methods, continuous manufacturing, and process intensification promise higher yields, reduced costs, and improved quality, shaping future sourcing strategies.
References
[1] U.S. Food and Drug Administration. Guidance for Industry: Chemistry, Manufacturing, and Controls Inbertramycin Injection.
[2] International Conference on Harmonisation. Q7. Good Manufacturing Practice Guide for Active Pharmaceutical Ingredients.
[3] Sinopharm. API Production Standards and Regulatory Approval Data.
[4] Jiangsu Hengrui Medicine. Annual Report 2022 – API Manufacturing Capabilities.
[5] Teva Pharmaceutical Industries. API Quality and Supply Chain Management.
More… ↓
